GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-03-13| Trials & Approvals

Pfizer’s Fast-Acting Migraine Nasal Spray Takes Home US Approval

by Joy Lin
Share To

The US FDA has approved Pfizer’s Zavzpret (zavegepant) nasal spray for the acute treatment of migraine in adults. Zavzpret is the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for this indication, the drugmaker said. 

The FDA approval adds to Pfizer’s list of approved treatments for acute migraine, including Nurtec (rimegepant). Zavzpret and Nurtec were the results of Pfizer’s $11.6 billion acquisition of Biohaven Pharmaceuticals in May 2022.   

Angela Hwang, Chief Commercial Officer of Pfizer, stated that Zavzpret’s approval marks a breakthrough for people with migraine who need freedom from pain and prefer something other than oral medications. 

“Pfizer will continue to build its migraine franchise to further support the billions of people worldwide impacted by this debilitating disease,” said Hwang. 

Zavzpret is expected to be available in pharmacies in July 2023. 

Zavzpret Shown to Provide Greater Pain and Symptom Relief Versus Placebo

Positive data from two pivotal studies on Zavzpret formed the basis of the US approval. In these studies, Zavzpret was shown to be statistically superior to placebo on the co-primary endpoints of pain freedom (defined as a reduction of moderate or severe headache to no headache) and freedom from most bothersome symptoms at two hours post-dose. 

On other endpoints, Zavzpret-treated patients experienced quicker pain relief and returned to normal function compared to placebo. In addition, relief was also found to be long-lasting. The results of the pivotal studies were published in The Lancet Neurology. 

“Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works,” said Kathleen Mullin, M.D., Associate Medical Director at New England Institute for Neurology & Headache.

“As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly.”

In terms of safety, Zavzpret was well tolerated. The most common side effects observed during clinical trials of Zavzpret included taste disorders, nausea, nasal discomfort, and vomiting. The drug is not suitable for patients who are hypersensitive to it or its components. Hypersensitive reactions such as facial swelling and breakout of rashes have occurred with Zavzpret in clinical studies.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top